| Date |
Title |
|
|
01/28/20
|
Alkermes Announces U.S. Food and Drug Administration Acceptance of ALKS 3831 New Drug Application for Treatment of Schizophrenia and Bipolar I Disorder
|
|
|
01/08/20
|
Alkermes' Corporate Presentation to be Webcast at the 38th Annual J.P. Morgan Healthcare Conference
|
|
|
12/12/19
|
Alkermes Media Statement Regarding FDA Warning Letter
|
|
|
11/26/19
|
Alkermes to Present at the Evercore ISI 2nd Annual HealthCONx Conference
|
|
|
11/25/19
|
Alkermes Completes Acquisition of Rodin Therapeutics
|
|
|
11/19/19
|
Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder
|
|
|
11/18/19
|
Alkermes to Acquire Rodin Therapeutics
|
|
|
11/12/19
|
Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences
|
|
|
11/12/19
|
Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY™
|
|
|
11/08/19
|
Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
|
|
|
11/04/19
|
Alkermes to Present Data From ALKS 4230 Clinical Development Program at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting
|
|
|
10/30/19
|
Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis
|
|
|
10/23/19
|
Alkermes Plc Reports Third Quarter 2019 Financial Results and Implementation of Restructuring
|
|
|
10/21/19
|
Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230
|
|
|
10/16/19
|
Alkermes to Host Conference Call to Discuss Third Quarter 2019 Financial Results
|
|
